The average wholesale price (AWP) at which Pfizer and Boehringer Ingelheim are launching tiotropium bromide [Spiriva] is 30% less than the AWP of GlaxoSmithKline's salmeterol/fluticasone propionate [Advair]

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.454, 2004-01, pp. : 11-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tiotropium bromide [Spiriva; Boehringer Ingelheim] has received final approval in Japan

By  

Inpharma, Vol. 1, Iss. 1465, 2004-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

GlaxoSmithKline stops salmeterol study

By  

Inpharma, Vol. 1, Iss. 1373, 2003-01 ,pp. : 24-24

Adis International

Access to resources Recommend Favorite

Tiotropium bromide [Spiriva; Boehringer Ingelheim] and peginterferon- -2b plus ribavirin [Peg-Intron plus Rebetol; Schering-Plough] have been recommended for approval

By  

Inpharma, Vol. 1, Iss. 1459, 2004-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite

The Big Three of US Pharma: Pfizer, Merck & Co. and GlaxoSmithKline

By  

Pharmaceutical Innovation, Vol. 11, Iss. 5, 2002-08 ,pp. : 46-49

Adis International

Access to resources Recommend Favorite

Salmeterol/Fluticasone Propionate Combination

By Spencer C.M.   Jarvis B.  

Drugs, Vol. 57, Iss. 6, 1999-06 ,pp. : 933-940

Adis International

Access to resources Recommend Favorite